Key Takeaways
- • Biotech displaced ICT as Switzerland's top-funded sector in H1 2025, receiving the largest share of venture capital allocation, reversing a multi-year trend where information and communication technology dominated investment flows.
- • Swiss venture capital investment rebounded 23.9% year-over-year to CHF 2.9 billion in 2025, with 124 financing rounds completed in the first half alone, signaling renewed investor confidence after two consecutive years of lower deployment.
- • ICT and fintech sectors contracted sharply, with fintech experiencing a 51.5% decline in invested capital and the broader ICT sector declining 12.9%, reflecting a structural shift in investor appetite away from traditional technology toward life sciences.
- • Deep Tech commands 60% of Swiss VC funding, positioning Switzerland as a leading European destination for capital-intensive, science-driven investments in biotech, medtech, and related advanced technology sectors.
- • Medtech emerged as the third major recipient of venture funding, advancing ahead of traditional ICT allocations and signaling institutional investor confidence in Switzerland's healthcare innovation ecosystem.
Summary
Switzerland's venture capital market experienced a significant sectoral rebalancing in 2025, with biotech startups and companies capturing the largest share of VC funding in the first half of the year—a marked departure from historical investment patterns. According to Statista's analysis of capital deployed between 2014 and 2025, biotech's ascendancy reflects broader investor preference for life sciences innovation over traditional information and communication technology (ICT) sectors that had historically dominated Swiss VC allocation.
The Swiss venture capital market demonstrated robust recovery momentum in 2025, with total investments reaching CHF 2.9 billion across the full year—a 23.9% increase from the prior year according to the Swiss Venture Capital Report and Venturelab data. This rebound follows two consecutive years of lower investment activity and signals renewed institutional confidence in the Swiss startup ecosystem. The first half of 2025 was particularly strong, with 124 financing rounds totaling CHF 1,473.7 million, representing the strongest half-year performance on record.
However, traditional technology sectors faced headwinds. Fintech experienced the most severe contraction, declining 51.5% in invested capital, while the broader ICT sector fell 12.9%. These declines occurred despite large investments in select deals, indicating a consolidation of capital around fewer, larger opportunities rather than broad-based funding. This sectoral shift reflects a structural reorientation of investor preference toward deep tech and life sciences solutions, where Switzerland maintains significant competitive advantages.
Deep Tech ventures—encompassing biotech, medtech, and advanced manufacturing—now represent approximately 60% of Swiss VC funding, reinforcing Switzerland's position as a premier European destination for capital-intensive, science-driven investments. Medtech's emergence as a primary funding destination, advancing ahead of traditional ICT, underscores institutional investor conviction in Switzerland's healthcare technology ecosystem. This diversification away from software and fintech toward hardware-intensive, regulated sectors represents a fundamental shift in the risk-return calculus driving institutional allocation decisions in Swiss venture markets.
The Swiss venture capital market demonstrated robust recovery momentum in 2025, with total investments reaching CHF 2.9 billion across the full year—a 23.9% increase from the prior year according to the Swiss Venture Capital Report and Venturelab data. This rebound follows two consecutive years of lower investment activity and signals renewed institutional confidence in the Swiss startup ecosystem. The first half of 2025 was particularly strong, with 124 financing rounds totaling CHF 1,473.7 million, representing the strongest half-year performance on record.
However, traditional technology sectors faced headwinds. Fintech experienced the most severe contraction, declining 51.5% in invested capital, while the broader ICT sector fell 12.9%. These declines occurred despite large investments in select deals, indicating a consolidation of capital around fewer, larger opportunities rather than broad-based funding. This sectoral shift reflects a structural reorientation of investor preference toward deep tech and life sciences solutions, where Switzerland maintains significant competitive advantages.
Deep Tech ventures—encompassing biotech, medtech, and advanced manufacturing—now represent approximately 60% of Swiss VC funding, reinforcing Switzerland's position as a premier European destination for capital-intensive, science-driven investments. Medtech's emergence as a primary funding destination, advancing ahead of traditional ICT, underscores institutional investor conviction in Switzerland's healthcare technology ecosystem. This diversification away from software and fintech toward hardware-intensive, regulated sectors represents a fundamental shift in the risk-return calculus driving institutional allocation decisions in Swiss venture markets.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.